Lung cancer is one of the tumors with the highest morbidity and mortality, and non-small cell lung cancer (NSCLC) accounts for about 85% of overall reported cases.[1] EGFR is a member of the ErbB receptor tyrosine kinase (TK) family, which plays a crucial role in the progression of NSCLC.[2] EGFR signaling has been reported to affect angiogenesis, activation and regulation of cell proliferation, and epithelial-mesenchymal transition. Here, EGFR is linked to lung cancer.